Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24611085 | 0.88 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL23848705 | 0.88 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL24462732 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL24462643 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL24611087 | 0.83 | BCL2 (0.31) | GABRA1GABRB1 | |
| SCHEMBL24040555 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL24462729 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL23848683 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL23569062 | 0.83 | TSHR (0.39) | GABRA1GABRB1 | |
| SCHEMBL24462653 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787811-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11384087-B1 | — | — | 2022-07-12 | — | — | US | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11345701-B1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11180506-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20210292331-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180506-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GABRA1 4281/4885GABRB1 4122/4885 |
| US-11384087-B1 | — | KRAS, NRAS, APC | GABRA1 4501/4885GABRB1 4139/4885 |
| US-11345701-B1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GABRA1 4155/4885GABRB1 3996/4885 |
| US-11787811-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GABRA1 4281/4885GABRB1 4122/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GABRA1 4281/4885GABRB1 4122/4885 |
| US-20210292331-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | GABRA1 4281/4885GABRB1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.